Biofil Chemicals & Pharmaceuticals Ltd (BIOFILCHEM)
🎯 Key Takeaways
- Biofil Chemicals & Pharmaceuticals Ltd is in a critical governance and strategic transition phase, marked by leadership continuity efforts and shareholder-driven decision-making. The company is navigating a turnaround scenario with declining profitability and stagnant growth, while management focuses on institutional legitimacy through director reappointments and AGM-driven resolutions.
- Revenue grew 63.1% QoQ to ₹12 in Q1FY27.
- ⚠️ Persistent profitability decline despite revenue fluctuations, with net profit falling to ₹10.91 lakhs from ₹241.10 lakhs, raising concerns about sust
- Market Cap
- ₹51
- P/E Ratio
- 105.0
- P/B Ratio
- 2.38
- ROE
- 2.2%
- ROCE
- 3.3%
- Debt/Equity
- 0.14
- Promoter
- 46.8%
📖 The Story
Biofil Chemicals & Pharmaceuticals Ltd is in a critical governance and strategic transition phase, marked by leadership continuity efforts and shareholder-driven decision-making. The company is navigating a turnaround scenario with declining profitability and stagnant growth, while management focuses on institutional legitimacy through director reappointments and AGM-driven resolutions. Despite stable promoter holding, weak investor confidence is reflected in negative returns and low ROE/ROCE, signaling operational headwinds.
📰 What's Happening
Recent board meetings have centered on reappointing Mr. Ashok Kumar Ramawat as Non-Executive Independent Director beyond age 75, requiring shareholder approval at the 41st AGM scheduled for 23 September 2026. The company has also sought approval for material related party transactions with Cyano Pharma up to INR 20 crores. Shareholders are being asked to endorse these governance decisions, which are critical for continuity but carry execution and approval risks. The board has consistently closed trading windows ahead of financial result disclosures, including for Q1 FY26 results announced on 11 August 2026, which showed revenue growth to ₹1,241.28 lakhs but a sharp decline in net profit to ₹10.91 lakhs.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 14 | 1 | 8 | 12 |
| Operating Profit | 0 | 0 | 0 | 0 |
| OPM % | 0.4% | 3.5% | 4.8% | 0.6% |
| Net Profit | 0 | 0 | 0 | 0 |
| EPS | ₹0.05 | ₹0.05 | ₹0.13 | ₹0.07 |
The company's financial trajectory shows mixed signals: revenue has fluctuated without clear upward momentum, rising to ₹12 lakhs in June 2026 from ₹8 lakhs in March 2026 but declining from a peak of ₹14 lakhs in September 2025. However, profitability has deteriorated significantly, with net profit collapsing from ₹241.10 lakhs in the prior period to just ₹10.91 lakhs in Q1 FY26, despite higher revenue. Operating margins remain volatile, and EPS has stagnated, indicating that revenue growth is not translating into sustainable earnings. This disconnect suggests pricing pressure, cost inefficiencies, or margin compression — factors management has not explicitly addressed in recent commentary.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue, margins, or growth targets in the latest filings. The focus remains on governance and shareholder approvals rather than strategic expansion or margin improvement initiatives. The reappointment of Mr. Ramawat and approval of related party transactions are framed as necessary for continuity, but no roadmap for financial recovery or operational turnaround is outlined. Investor communication appears limited to procedural updates, with no discussion of product pipelines, market expansion, or cost restructuring to address declining profitability.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 |
| Reserves | 3 | 2 | 5 | 5 |
| Borrowings | 0 | 0 | 3 | 0 |
| Total Liabilities | 51 | 42 | 43 | 55 |
| Fixed Assets | 8 | 8 | 7 | 7 |
| Investments | 0 | 0 | 0 | 0 |
| Total Assets | 51 | 42 | 43 | 55 |
The balance sheet shows minimal leverage with near-zero borrowings and stable equity of ₹16 crores, suggesting a conservative capital structure. However, total assets have fluctuated without clear growth, declining slightly from ₹55 crores in March 2026 to ₹43 crores in the latest quarter, indicating possible asset disposals or revaluations. Reserves remain low at ₹5 crores, and the lack of debt is not offset by reinvestment or cash generation, as cash flow from operations has been negative. This implies limited financial flexibility and a lack of aggressive capital allocation strategy despite stable promoter stake.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -2 |
| Investing | -0 |
| Financing | -0 |
| Net Cash Flow | -2 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 46.8% | 46.8% | 46.8% | 46.8% |
| FII | 0.0% | 0.0% | 0.0% | 0.0% |
| DII | 0.1% | 0.1% | 0.1% | 0.1% |
| Public | 38.2% | 38.3% | 38.4% | 38.6% |
| # Shareholders | 25,196 | 24,825 | 25,356 | 24,999 |
Promoter holding remains stable at 46.79% with no signs of dilution, but institutional interest is negligible — FII holding is flat at 0% and DII at just 0.08%, suggesting minimal investor confidence. The small public float and high number of shareholders (24,999) indicate retail dominance, but low trading volumes and stagnant institutional inflows reflect limited market appeal. There are no signs of activist accumulation or strategic investor interest, and the lack of FII/DII growth reinforces concerns about visibility and liquidity.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent profitability decline despite revenue fluctuations, with net profit falling to ₹10.91 lakhs from ₹241.10 lakhs, raising concerns about sustainable earnings. 2. Governance risk tied to the reappointment of Mr. Ramawat beyond retirement age, which depends on shareholder approval and may face regulatory or voting scrutiny. 3. Lack of institutional investor interest and near-zero DII/FII holdings signal limited confidence in the company's turnaround prospects. 4. Operational opacity, with minimal management commentary on growth drivers or margin improvement strategies despite recurring financial underperformance.
📋 Recent Filings
- 🟡 Board Meeting2026-09-24Biofil Chemicals announced the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director for one more term after he turned 75, c…
- 🟡 voting results2026-09-24At the 41st AGM on 23 September 2026, shareholders approved all four resolutions via remote e-voting and in-person voting, with near-unanimous approva…
- Announcement2026-09-24Biofil Chemicals & Pharmaceuticals Ltd announced the closure of its insider trading window effective October 1, 2026, to cover the upcoming un-audited…
- 🟡 Board Meeting2026-09-23Biofil Chemicals held its 41st AGM on 23 September 2026 via video conference, confirming quorum and remote e-voting compliance. Shareholders approved …
- 🔴 annual report2026-08-26Biofil Chemicals & Pharmaceuticals Limited announced its 41st Annual General Meeting scheduled for 23 September 2026 via video conference. Shareholder…
- 🟡 Board Meeting2026-08-26Biofil Chemicals announced that shareholders can vote electronically for its 41st Annual General Meeting on 23 September 2026 at 3:00 PM IST via video…
- 🟡 Board Meeting2026-08-11Biofil Chemicals & Pharmaceuticals announced board approval of unaudited Q1 FY26 results showing revenue of **₹1,241.28 lakhs**, up from **₹926.46 lak…
- 🟡 Board Meeting2026-08-11Biofil Chemicals announced the continuation of Mr. Ashok Kumar Ramawat as a Non-Executive Independent Director despite reaching age 75, requiring shar…
- share transfer2026-07-01Biofil Chemicals & Pharmaceuticals Limited received a SEBI-mandated confirmation certificate from its share transfer agent, Ankit Consultancy Pvt Ltd,…
- Financial Results2026-06-25Biofil Chemicals & Pharmaceuticals Limited announced that its trading window for insider transactions will close on Wednesday, July 1, 2026, to facili…
🧠 Analyst's Read
The company is in a fragile phase where governance decisions are taking precedence over financial recovery, and without a clear strategy to improve margins or generate sustainable profits, investor confidence remains weak. Key near-term triggers will be the outcome of the 41st AGM and the market's reaction to the upcoming unaudited financial results, which will test whether recent revenue trends can be sustained with improved cost control.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when BIOFILCHEM files new disclosures
Track BIOFILCHEM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BIOFILCHEM — FreeFree account · 2 AI queries/day